[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].

Takatoku, Masaaki; Noborio-Hatano, Kaoru; Takahashi, Satoko; Kikuchi, Satoru; Mori, Masaki; Muroi, Kazuo; Komatsu, Norio; Ozawa, Keiya

Takatoku, Masaaki; Noborio-Hatano, Kaoru; Takahashi, Satoko; Kikuchi, Satoru; Mori, Masaki; Muroi, Kazuo; Komatsu, Norio; Ozawa, Keiya.

Rinsho Ketsueki ; 45(2): 144-8, 2004 Feb.

Article in Ja | MEDLINE | ID: mdl-15045823

Subject(s)

Antineoplastic Agents/therapeutic use; Boronic Acids/therapeutic use; Multiple Myeloma/drug therapy; Protease Inhibitors/therapeutic use; Pyrazines/therapeutic use; Antineoplastic Agents/administration & dosage; Boronic Acids/administration & dosage; Bortezomib; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Protease Inhibitors/administration & dosage; Pyrazines/administration & dosage; Thalidomide/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Protease Inhibitors / Pyrazines / Boronic Acids / Multiple Myeloma / Antineoplastic Agents Language: Ja Journal: Rinsho Ketsueki Year: 2004 Type: Article

Search on Google

Add to My VHL

XML

PubMed Links